OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Virology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Editorial Board	192
Colonization of peripheral ganglia by herpes simplex virus type 1 and 2	146
Hepatitis-B virus: replication cycle, targets, and antiviral approaches	95
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19	91
Inhaled aerosol viral-vectored vaccines against tuberculosis	79
Mutational escape from cellular immunity in viral hepatitis: variations on a theme	69
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?	69
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy	66
The enigmatic roles of Anelloviridae and Redondoviridae in humans	57
Transmission patterns of hepatitis E virus	54
Editorial Board	52
Structural basis for neutralization of enterovirus	49
Virus–host protein interactions as footprints of human cytomegalovirus replication	48
Editorial overview: Viral pathogenesis	47
Human placental models for studying viral infections	44
Viral–host interactions during splicing and nuclear export of influenza virus mRNAs	44
Editorial Board	43
Recent progress in development of monoclonal antibodies against human cytomegalovirus	41
New preventive strategies for respiratory syncytial virus infection in children	40
Time to ‘Mind the Gap’ in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2	40
The two faces of oligoadenylate synthetase-like: effective antiviral protein and negative regulator of innate immunity	40
Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1	38
Paramyxoviruses from bats: changes in receptor specificity and their role in host adaptation	37
The journey of herpesvirus capsids and genomes to the host cell nucleus	35
Shopping for phages? Unpacking design rules for therapeutic phage cocktails	32

Emerging technologies in the study of the virome	32
Epigenetic control of the Epstein-Barr lifecycle	32
Platelets in the pathogenesis of flavivirus disease	30
A review of broadly protective monoclonal antibodies to treat Ebola virus disease	29
Mitigation of evolved bacterial resistance to phage therapy	29
Perspective on taxonomic classification of uncultivated viruses	28
A complex immune communication between eicosanoids and pulmonary macrophages	28
Asymmetry in icosahedral viruses	27
The enigma of picobirnaviruses: viruses of animals, fungi, or bacteria?	27
Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome: challenges and opportunities	27
Engineering therapeutic phages for enhanced antibacterial efficacy	27
Editorial Board	27
When good turns bad: how viruses exploit innate immunity factors	26
Retasking of canonical antiviral factors into proviral effectors	26
Does arbovirus emergence in humans require adaptation to domestic mosquitoes?	25
Human organoid models to study coronavirus infections of the respiratory tract	24
Hemagglutinin stability as a key determinant of influenza A virus transmission via air	24
Tissue-resident memory T cells in protective immunity to influenza virus	24
Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity	24
Immune responses to human respiratory coronaviruses infection in mouse models	23
Modeling zoonotic and vector-borne viruses	23
Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy	23
Mechanisms of HCV resistance to broadly neutralizing antibodies	23
MicroRNA-mediated control of Epstein–Barr virus infection and potential diagnostic and therapeutic implications	23
Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets	23
MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases	22
Diagnosis and monitoring of virus-associated cancer using cell-free DNA	22
Role of the viral polymerase during adaptation of influenza A viruses to new hosts	21
Deimmunization of flagellin adjuvant for clinical application	21
Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity	20
State-of-the-art in oncolytic virotherapy using adenoviruses other than the commonly applied adenovirus type 5	20
Oncogenic Animal Herpesviruses	20